Skønt der i visse af undersøgelserne fra de sidste fem år er opnået lavere antistoftiter med hepatitis B - vacciner end i begyndelsen af 1990' erne, viser de kliniske data, der er genereret af sponsoren i de ovenfor beskrevne undersøgelser, et ensartet højt beskyttelsesniveau af anti- HBs i serum, som er det anerkendte korrelat for virkning.
Although in some of the trials conducted in the past 5 years, the GMTs of the hepatitis B vaccines were lower than responses observed in the early 1990’ s, the clinical data generated by the sponsor in the trials described above, demonstrate consistent, high anti-HBs seroprotective rates, which is the established correlate of effectiveness.